Antibe Therapeutics Inc (ATE.TO)
0.295
0.00 (0.00%)
CAD |
TSX |
May 17, 16:00
Antibe Therapeutics Net Income (Quarterly): -4.213M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.213M |
| September 30, 2023 | -5.006M |
| June 30, 2023 | -5.786M |
| Date | Value |
|---|---|
| March 31, 2023 | -3.548M |
| December 31, 2022 | -4.316M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-5.786M
Minimum
Jun 2023
-3.548M
Maximum
Mar 2023
-4.574M
Average
-4.316M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Biocure Technology Inc | -4.008M |
| Core One Labs Inc | -0.8407M |
| Nova Mentis Life Science Corp | -0.1841M |
| Nanosphere Health Sciences Inc | -0.0748M |
| Lobe Sciences Ltd | -0.5955M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.596M |
| EPS Diluted (Quarterly) | -0.08 |
| Enterprise Value | -9.370M |
| Earnings Yield | -118.6% |